16-hydroxycleroda-3,13(14)-dien-15,16-olide has been researched along with imatinib mesylate in 1 studies
*Imatinib Mesylate: A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. [MeSH]
*Imatinib Mesylate: A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. [MeSH]
| Studies (16-hydroxycleroda-3,13(14)-dien-15,16-olide) | Trials (16-hydroxycleroda-3,13(14)-dien-15,16-olide) | Recent Studies (post-2010) (16-hydroxycleroda-3,13(14)-dien-15,16-olide) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 13 | 0 | 8 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | 16-hydroxycleroda-3,13(14)-dien-15,16-olide (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, WL; Chang, JG; Chang, WH; Lee, CC; Lin, YH; Wu, YC | 1 |
1 other study(ies) available for 16-hydroxycleroda-3,13(14)-dien-15,16-olide and imatinib mesylate
| Article | Year |
|---|---|
16-Hydroxycleroda-3,13-dien-15,16-olide deregulates PI3K and Aurora B activities that involve in cancer cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Diterpenes; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Serine-Threonine Kinases; Pyrimidines; Signal Transduction | 2011 |